Today Janssen has received U.S. FDA approval of SIMPONI ARIA® for the treatment of adults living with active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS).
Today’s approvals follow the first FDA approval of SIMPONI ARIA® in 2013 for the treatment of moderately to severely active rheumatoid arthritis (RA). We are proud these expanded indications will provide a new treatment option for those living with such debilitating conditions such as PsA and AS, especially one that offers a 30-minute infusion time and as few as 6 times a year.
- The multimedia news release and important safety info can be found here: http://po.st/VPZfbL
- We also shared via @JanssenUS: https://twitter.com/JanssenUS/status/921480303113318400